A small randomized trial in Spain demonstrated that treating Helicobacter pylori (H. pylori) infected individuals with probiotic therapy in addition to an eradication regimen improved symptoms of distension and stomach pain compared to those who got the eradication regimen plus placebo. probioticseverything.comprobiotics h pylori reddit
According to Blas José Gómez Rodrguez, MD, of Hospital Universitario Virgen Macarena in Sevilla, Spain, and colleagues, among 80 patients receiving bismuth-containing quadruple eradication therapy, abdominal pain symptoms decreased in 42 percent of those given the probiotic (Lactobacillus reuteri) versus 19 percent of those given placebo (OR 0.27, CI 0.13-0.58, P0.001).
Furthermore, the intervention group had a lower rate of abdominal distention than the control group (25 percent vs 17 percent, respectively; OR 0.24, 95 percent CI 0.19-0.84, P0.001), according to the authors in the Spanish Journal of Gastroenterology. probioticseverything.comprobiotics h pylori reddit
The authors noted, “Probiotics show promising effects as therapeutic adjuvants, minimizing associated side events.” “Further research into probiotic therapies as adjuvant therapy is needed, and patients with a more symptom-specific profile should be included in studies with longer follow-up intervals.” probioticseverything.comprobiotics h pylori reddit
Previous research has shown that L. reuteri strains combined with triple antibiotic therapy are effective in eradicating H. pylori infections in patients all over the world, and studies using quadruple therapy have yielded successful eradication results, including a 2019 study from Thailand that reported a 96 percent H. pylori eradication rate after 14 days in patients treated with bismuth and L. reuteri. probioticseverything.comprobiotics h pylori reddit
Prior studies of quadruple therapy with bismuth and probiotics had similar high success rates in eradicating H. pylori, but showed substantial adverse event rates in patients, leading to noncompliance. probioticseverything.comprobiotics h pylori reddit
The scientists used a double-blind, randomized, placebo-controlled, parallel-armed clinical experiment to see if adding L. reuteri to the diet could alleviate or lessen gastrointestinal symptoms as judged by the Gastrointestinal Symptom Rating Scale (GSRS). probioticseverything.com
Adults between the ages of 18 and 65 who had a proven H. pylori infection and had not previously taken any other drugs were eligible. probioticseverything.comprobiotics h pylori reddit
From February 2018 to May 2019, a total of 80 patients received quadruple eradication therapy, consisting of bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride (three in one/capsule; doses of 140 mg, 125 mg, and 125 mg, respectively) given as three capsules four times per day plus omeprazole 40 mg twice daily for ten days. probioticseverything.comprobiotics h pylori reddit
For a month, patients were given either the L. reuteri probiotic or a placebo tablet. At 0, 14, 28, and 56 days, adverse events were documented.
A little more than half of the patients were women, with a median age of 50. The only difference between treatment groups was that the control group had considerably higher gastrointestinal comorbidities (7.5 percent vs 27.5 percent in the probiotic group; P=0.039), which included ulcerative colitis and Crohn’s disease. In both groups, the median number of therapy days was 10.
Overall, eradication therapy was successful in 85 percent of patients, with no statistically significant differences in eradication rates between groups. Other symptoms, such as acid reflux, flatulence, and heartburn, improved in both patient groups. probioticseverything.comprobiotics h pylori reddit
Except for one patient in the control group who dropped out due to skin rash, glossitis, and vomiting, there were 20 adverse events reported in 16 patients, all of which were mild to moderate in intensity.
The use of randomization was a study constraint, as it may have biased data results for the probiotic group, resulting in greater ratings for dyspeptic syndrome and distension syndrome.
The study group participants may have been chosen using stricter restriction criteria, according to the authors. Furthermore, higher symptom reductions by using probiotics could have been detected if more individuals with dyspeptic syndrome were chosen. Another flaw was that follow-up was determined by GSRS sensitivity, which may have been insufficient to assess probiotic benefits.